A CLEARER FUTURE
RELIEVE THE BURDEN OF ROSACEA1,2
Help your rosacea patients
achieve clearer skin
As a healthcare professional, your role is vital in supporting your patients throughout their rosacea journey, working with them to relieve the physical, social and emotional burden of their disease2
By developing a maintenance plan, you can actively help control their rosacea symptoms, driving them towards achieving clearer skin with the goal of IGA 01,2*
“After talking with my dermatologist,
I finally feel like I can help control my
rosacea – it’s liberating!”
The importance of aiming for ‘clear’ (IGA 0) as a treatment goal vs ‘almost clear’ (IGA 1):1,2
Disease impact
Achieving ‘clear’ improves the quality of life for 1 in 2 rosacea patients, significantly more than ‘almost clear’2
Time to relapse
Rosacea patients who reached ‘clear’ had a longer time to relapse, and when they did relapse, they responded faster to treatment compared to ‘almost clear’2
Patient satisfaction
Rosacea patients who are ‘clear’ tend to say their work productivity is unaffected and have a lower number of doctor visits vs those who are almost ‘clear’2
Oracea capsules
For rosacea patients, the benefits of ‘clear’ (IGA 0) can
go beyond symptom improvement1,2
*IGA, Investigator’s Global Assessment
STAY CONNECTED
Sign up and
stay up-to-date
For the latest news, research, and insights into papulopustular rosacea, subscribe now! You’ll also receive patient resources and toolkits, helping you treat your patients throughout their rosacea journey
Important Safety Information
Indication: ORACEA® (doxycycline) 40 mg* capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA does not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in subjects treated with ORACEA were nasopharyngitis, diarrhea, hypertension and sinusitis. Warnings/Precautions: ORACEA should not be used to treat or prevent infections. ORACEA should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years) and may cause reversible inhibition of bone growth. If Clostridium difficile associated diarrhea (CDAD) occurs, may need to discontinue ORACEA. Although photosensitivity was not observed in clinical trials, ORACEA patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA treatment beyond 16 weeks and safety beyond 9 months have not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*30 mg immediate release and 10 mg delayed release beads
REFERENCES
1. Schaller M, et al. Recommendations for rosacea diagnosis, classification and management: Update from the global ROSacea COnsensus (ROSCO) 2019 panel. British Journal of Dermatology. 2019. doi: 10.1111/ bjd.18420. [Epub ahead of print]. 2. Rosacea: Beyond the visible report. Available at: https://hosted.bmj.com/rosaceabeyondthevisible. Accessed: September 2021
